Australian clinics cannot advertise discounts on prescription-only injectables to the general public under the Therapeutic Goods Act 1989. These treatments are classified as prescription medicines, and public price promotions -- on your website, social media or in email campaigns -- breach the advertising restrictions. Compliant revenue growth comes from loyalty programs, membership perks and private pricing conversations with existing clients.
In short: public advertising of injectable discounts is prohibited; loyalty and membership programs structured correctly sit outside that restriction.
Why does the TGA restrict advertising of injectable treatments?
Most cosmetic injectables used in Australian clinics -- anti-wrinkle injections and many dermal fillers -- are prescription-only medicines under Australian scheduling law. The Therapeutic Goods Administration (TGA), the national regulator for medicines and medical devices, classifies these substances as Schedule 4 (Prescription Only) medicines under the Poisons Standard.
Section 42DL of the Therapeutic Goods Act 1989 prohibits advertising prescription medicines to the general public. The rationale is patient safety: prescription medicines require a clinical assessment by a qualified practitioner before they can be administered. Advertising designed to stimulate demand for a prescription medicine -- including promotional pricing -- bypasses that safeguard by encouraging self-referral based on a price signal rather than clinical need.
This restriction is not specific to cosmetic use. It applies equally to antibiotics, blood pressure medications and injectable cosmetic treatments. The cosmetic context does not create an exemption.
AHPRA's advertising guidelines apply separately to registered practitioners (nurses, doctors) and independently prohibit advertising that is false, misleading or likely to create unrealistic expectations. For a full overview of how both regulatory frameworks apply to cosmetic clinic advertising, see our guide to AHPRA cosmetic advertising guidelines.
What does the advertising prohibition actually cover?
The prohibition covers any communication made to the general public that is designed to promote the use or supply of a prescription medicine. The medium does not matter: website pages, Instagram posts, Facebook ads, Google display ads, email newsletters, SMS broadcasts, printed flyers and signage in your clinic's window all count as advertising if they can be seen by the general public.
Promotional price communications that breach the restriction include:
- Discount offers on specific injectable treatments publicly advertised
- Seasonal promotions referencing injectable treatments by name or category
- Price lists for injectable treatments published on your website or social media
- "Package deal" advertising that identifies specific prescription injectable products
- Buy-one-get-one or area-bundling promotions publicly advertised for injectable services
The table below shows how common promotional approaches map against the restrictions:
| Promotional approach | Publicly advertising to general public | Notes |
|---|---|---|
| Discount offer on a named injectable treatment, published on social media | Not permitted | Advertising a prescription medicine to the public |
| Injectable pricing list on clinic website | Not permitted | Constitutes advertising prescription medicines publicly |
| Seasonal promotion referencing injectable treatments | Not permitted | Applies regardless of whether medicine is named or implied |
| Loyalty points earned on all clinic spending including injectable treatments | Permitted | Points rewarded for clinic spend, not advertising a specific medicine |
| Clinic membership with priority booking, retail rewards and general perks | Permitted | Membership benefits are not advertising a prescription medicine |
| General "treat yourself this month" content without naming treatments | Generally permitted | Non-specific; does not promote a prescription medicine |
| Educational content explaining how a category of treatment works | Generally permitted | Educational, not promotional in the advertising sense; seek specific advice |
| Private pricing discussion in a clinical consultation with an existing patient | Different context from public advertising | Not a public communication; seek legal advice for your specific situation |
This article is general information, not legal advice. The application of the Therapeutic Goods Act and AHPRA guidelines to specific advertising is fact-dependent. If you are uncertain whether a planned promotion breaches the rules, seek advice from a healthcare advertising compliance specialist before publishing.
Can clinics discuss injectable pricing privately with existing clients?
The TGA advertising restrictions target public communications -- communications made to the general public or to a section of the public. A private pricing conversation that takes place during a clinical consultation with an individual patient is a materially different context from a public advertisement.
There is a meaningful difference between a practitioner responding to a patient who asks "how much does this treatment cost?" in a consultation, and a social media post promoting a discount on that treatment to every follower. The first is a clinical communication; the second is advertising.
However, the line between a private clinical communication and a promotional communication is not always clear-cut, particularly when digital communications are involved. An email sent to your entire client database promoting a pricing offer could be treated as advertising even if sent only to existing clients. Clinics should seek specific legal advice before implementing any price-based communication strategy that extends beyond one-on-one consultations.
What compliant alternatives grow injectable revenue without breaking the rules?
The restriction on public injectable advertising does not mean cosmetic clinics are limited in how they grow revenue. Several strategies are both commercially effective and structurally consistent with the advertising rules:
- Loyalty programs that reward all clinic spending. A points-on-spend program rewards clients for every dollar they spend across all services and retail at your clinic, including injectable treatment sessions. The program itself is not advertising injectables -- it is a retention mechanism that makes every visit more valuable to the client.
- Membership tiers with general perks. A clinic membership that offers priority booking, retail discounts, quarterly credits or member-exclusive events is a relationship product, not injectable advertising. Clients value the status and convenience; you build predictable recurring revenue. For a detailed look at how to structure membership tiers, see our guide to clinic membership tiers clients actually want.
- Event-based engagement. Member evenings, skin consultations and educational workshops build loyalty without any promotional claim about specific treatments or pricing.
- Premium experience positioning. Clinics that invest in a seamless, premium client experience -- branded app, visible loyalty balance, personalised communications -- build a competitive advantage that does not depend on price signals.
The clinics growing injectable revenue fastest are not competing on price. They are competing on the experience: a client who feels genuinely valued comes back more often and refers more readily than one who came in for a discount.
How do loyalty programs fit with the injectable advertising rules?
A well-structured loyalty program is not advertising a prescription medicine. It is a retention mechanism that rewards clients for spending at your clinic across all services. The key is that the program rewards behaviour (visiting, spending) rather than promoting a specific prescription medicine or its price.
For injectable treatments specifically, the distinction that matters is this: your loyalty program can acknowledge that a client has completed a treatment session and award points accordingly, without publicly promoting that treatment, naming the medicine administered, or advertising a discounted price to attract new clients.
The rules that govern loyalty and membership programs in the context of TGA and AHPRA advertising requirements are worth reading in full if you operate a cosmetic injectable clinic. The short version: reward the relationship, not the medicine.
Clinics that build a structured loyalty and membership program alongside their injectable services consistently see higher repeat-visit rates and higher average spend per client -- not because of discounting, but because clients who feel connected to a clinic return more frequently and buy more at each visit. The maths of retention outperform the maths of discounting every time.
Frequently asked questions
Can Australian cosmetic clinics advertise discounts on injectables?
No. The Therapeutic Goods Act 1989 prohibits advertising prescription medicines to the general public, and most cosmetic injectables are classified as prescription-only medicines. Publicly promoting injectable discounts -- on your website, social media or in email campaigns -- breaches these advertising restrictions.
What happens if a clinic advertises injectable prices or discounts publicly?
The TGA can require the advertising to be removed and may issue infringement notices or refer matters for prosecution. AHPRA can separately investigate registered practitioners whose advertising breaches its guidelines. Both regulators have expanded their monitoring of digital and social media advertising.
Do loyalty programs count as advertising injectables?
A loyalty program that rewards clients for spending at your clinic -- without publicly promoting or naming specific prescription medicines -- operates differently from injectable advertising. Points earned on all treatments, or membership tiers that include priority booking and general rewards, do not constitute advertising a prescription medicine.
Can clinics discuss injectable pricing privately with existing clients?
The TGA advertising restrictions apply to public communications designed to attract new clients. A private pricing conversation during a clinical consultation with an existing patient is a different context. Clinics should seek specific legal advice for their situation, as the line between a private communication and advertising is fact-dependent.
